Replies to post #6711 on Cytodyn Inc (CYDY)

[Northstar42]

I could not agree more, very well said.

[buckysherm]

It's not playing with the stock price, it's allowing more institutional investors a chance to go long Cydy. It wouldn't take much for a fund or rtf to dwarf the current volume. Wont happen until an uplist. On otc, the shorts rule until approval.

[5TOP]

While I appreciate your positive attitude there are a few points that you made that are very wrong.

they are not doing themselves any favors by reaching for straws (eg. management spending valuable resources to promote, playing with the price by doing a reverse split, demanding insiders buy more, etc.)

Im sorry but these things are HARDLY "reaching for straws". As a rule of thumb, and this is absolutely true for the vast, vast, vast majority of both retail and institutional investors, I wont even look at, let alone consider buying an OTC stock. Why? Because statistically about 90% of stocks that trade on the OTC exchange are either scams, trading in the darker corners of the stock market due to lesser regulation and transparency requirements, or they are failing corporations on their way to the dust bin. So why would I or anyone else for that matter take a hard look at making a long term investment in CytoDyn? Because their science is great? Being new to the name, I dont know that. Why would I take all the time to do the necessary DD to invest when I can clearly see that the CEO isnt even invested? Maybe thats not part of your investment thesis, and thats fine but for myself and many, many others, insider ownership is a very important indicator of the belief and commitment of management to the future of their company. Im not saying this is a deal breaker right off the bat but for me its essentially a + - point in a scoring procedure. Ok so why else would I look at CYDY? Institutional ownership? Nope, trades on OTC. Big names talking about it? Nope, not yet. A fair to good looking long term chart? Not going to grab my attention. My point is that CYDY is virtually unknown and no one is going to pour the time into the research needed to invest when theres little to intrigue them on the surface. Is CYDY a diamond in the rough? Absolutely, but its still buried in the mountain at this point.

Promoting the vision before the FDA approves it, is money down the drain. When the FDA approves, when revenue starts flowing in, and the fundamentals justify a significant increase in the value of the shares, only then will the "red" in your investments go back into the "black." As I said in my previous post, until then, all the movement in price is just "static," meaningless "noise" if you will.

Promoting is NOT money down the drain when you are trading this far below a fair valuation. When we offer at this level we are selling our company for a fraction of its present value. This has long term consequences. This isn't about being in the "red" or being in the "black".

From my post #6699

As I have said before my only concern for short term price movements is at what price we raise cash. If we are offering at 0.75 vs 1.50 or 2.25 then we have to sell double or triple the shares to raise the same amount of cash. And that also doubles or triples the dilutive effect. If that is done over and over and over, you end up diluting down a substantial amount of your fully developed share price. Will you still make it to the finish line and make money? Yes, but you could be looking at a pretty drastic reduction in your ROI. So with this in mind you can see how important it is ensure your share price matures with your other developments. Its definitely not all about making a quick buck.

Insider buying, stock promotion, uplisting are very valuable tools at our disposal that aren't being used. We are continuing to sell stock at the same levels regardless of the substantial progress we have made with PRO-140. This is unacceptable. I would accept it if I could at least see that management was making an effort to correct this problem. I dont see that. What I see is all the focus on the science development and very little focus on the business development. The science is not and will not sell itself. Especially when we are trading OTC and you have to take a very close look to find it. (Diamond buried in the mountain) Yes it will be much easier to sell, and to a degree it will sell itself, once we have FDA approval but how much more of our company will we offer unnecessarily before we get there?

If you believe in the concept, believe in the company, hold your shares or even buy more, and most of all, be patient. You all knew that before you bought in.

I completely agree with this. But at the same time I think its important to make corrections in our course that will have long term benefits for all. And selling stock at a fraction of its present value is not benefiting anyone.